Cochrane for Clinicians: Putting Evidence into Practice
Screening for and Treating Asymptomatic Bacterial Vaginosis in Pregnancy
FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.
FREE PREVIEW. Purchase online access to read the full version of this article.
Am Fam Physician. 2002 Sep 1;66(5):780-783.
A 24-year-old woman, gravida 2, para 1, who has no history of preterm labor, presents at 13 weeks' gestation for prenatal care. She has no complaint of vaginal discharge.
Should you perform screening for and, if the results are positive, treat asymptomatic bacterial vaginosis (BV) during this pregnancy?
No. Screening for and treating BV in pregnant women who are at low risk for preterm delivery does not lower the risk of preterm delivery. If this patient were at high risk for preterm delivery (i.e., a history of preterm delivery or underweight before pregnancy), it would be reasonable to screen for BV and treat if the results are positive.
Background. BV has been associated with poor perinatal outcome. Because the infection is amenable to treatment, identification and treatment during pregnancy may reduce the risk of preterm birth and its consequences.
Objectives. The objective of this review was to assess the effects of antibiotic treatment of BV in pregnancy.
Search Strategy. The authors searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register.
Selection Criteria. Randomized trials comparing one antibiotic regimen with placebo or no treatment, or comparing two or more alternative antibiotic regimens in pregnant women with BV were included.
Data Collection and Analysis. Trial quality assessments and data extraction were done independently by three reviewers. Study authors were contacted for additional information.
Primary Results. Five trials involving 1,504 women were included. These trials were of good quality. Antibiotic therapy was highly effective in eradicating infection during pregnancy, as judged by “test-of-cure” following therapy (odds ratio [OR], 0.22; 95 percent confidence interval [CI], 0.17 to 0.27). The effect of treating BV during pregnancy showed a trend toward fewer births before 37 weeks' gestation (OR, 0.78; 95 percent CI, 0.60 to 1.02). The prevention of preterm birth at less than 37 weeks' gestation was most marked in the subgroup of women with a previous preterm birth (OR, 0.37; 95 percent CI, 0.23 to 0.60).
Reviewer's Conclusions. The current evidence does not support screening and treating all pregnant women for BV to prevent preterm birth and its consequences. In women with a history of a previous preterm birth, there is some suggestion that detection and treatment of BV early in pregnancy may prevent a proportion of these women from having a further preterm birth. It is not known whether this outcome is associated with an improvement in neonatal well-being.1
These summaries have been derived from Cochrane reviews published in the Cochrane Database of Systematic Reviews in the Cochrane Library. Their content has, as far as possible, been checked with the authors of the original reviews, but the summaries should not be regarded as an official product of the Cochrane Collaboration; minor editing changes have been made to the text (http://www.cochrane.org)
Did the authors address a focused clinical question ? Yes.
Were the criteria used to select articles for inclusion appropriate? Yes. They noted that one of the trials they included did not use an intention-to-treat analysis, which slightly weakened their conclusions.
Is it likely that important relevant articles were missed? No.
Was the validity of the individual articles appraised? Yes.
How precise are the results? Reasonably precise. The authors mentioned that only those data that were not heterogeneous were subjected to meta-analysis, but they did not explicitly describe the analyzed data as being non-heterogeneous.
Can the results be applied to patient care? Yes.
Do the conclusions make biologic and clinical sense? Yes.
Are the benefits worth the harms and costs? Although a formal cost-benefit analysis is not part of the Cochrane critique, it is reasonable to hope that, in patients with a history of preterm labor, screening for and treating BV may be cost-effective.2
In women who are not at high risk of preterm delivery, the evidence does not support screening for and treatment of asymptomatic BV. This statement is consistent with recent guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the U.S. Preventive Services Task Force (USPSTF).3,4
Since the publication of the Cochrane review,1 three clinical trials and one meta-analysis have been published that confirm this recommendation.3,5–7 In 2000, Kurkinen-Räty and colleagues6 reported finding no decrease in preterm delivery rates in 101 women who had been randomized to receive vaginal clindamycin or placebo.6 In a larger randomized controlled trial5 published in 2000,1,953 asymptomatic women from a general obstetric population were screened for BV and, if positive, treated with oral metronidazole or placebo. Carey and colleagues reported no reduction in rates of preterm labor or other outcomes. In 2001, Kekki and colleagues6 reported no effect of screening for and treating asymptomatic BV on preterm delivery in 375 healthy singleton women who were randomized to receive vaginal clindamycin or placebo.
In a quick calculation summing up the rates of preterm delivery from the three studies included in the Cochrane meta-analysis and the three new studies, the overall rate of preterm delivery is identical in antibiotic and control groups—12.7 percent. It will take another meta-analysis to properly compare these two, now enlarged, groups.
A meta-analysis by Guise and colleagues3 confirms that screening for and treating asymptomatic BV does not decrease preterm birth. While this meta-analysis includes the large study by Carey and colleagues,5 it does not include the smaller studies done by Kekki and Kurkinen-Räty.6,7
In high-risk women (i.e., those who have had a previous preterm delivery), some evidence supports screening for BV and treating only women with positive results. In this high-risk population, the number needed to treat can be calculated to be 5 using the data from the Cochrane review.1
Currently, ACOG recommends against screening and treating high-risk women.4 The USPSTF concludes that “a subgroup of high-risk women may benefit from screening and treatment; however, there may be a subgroup for whom BV treatment could increase the occurrence of preterm delivery.”3Figures 1 and 2 summarize outcome with antibiotic therapy or placebo in all women and in those with a history of preterm labor.
REFERENCESshow all references
1. Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2000;2:CD000262....
2. Muller E, Berger K, Dennemark N, Oleen-Burkey M. Cost of bacterial vaginosis in pregnancy. Decision analysis and cost evaluation of a clinical study in Germany. J Reprod Med. 1999;44:807–14.
3. Guise JM, Mahon SM, Aickin M, Helfand M, Peipert JF, Westhoff C. Screening for bacterial vaginosis in pregnancy. Am J Prev Med. 2001;20(3 suppl):62–72.
4. ACOG Practice Bulletin. Assessment of risk factors for pretermbirth. Clinical management guidelines for obstetrician-gynecolo gists. Number 31. Obstet Gynecol. 2001;98:709–16.
5. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med. 2000;342:534–40.
6. Kekki M, Kurki T, Pelkonen J, Kurkinen-Räty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol. 2001;97(5 pt 1):643–8.
7. Kurkinen-Räty M, Vuopala S, Koskela M, Kekki M, Kurki T, Paavonen J, et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG. 2000;107:1427–32.
The Cochrane Abstract is a summary of a review from the Cochrane Library. It is accompanied by an interpretation that will help clinicians put evidence into practice. Rabin Chandran, M.D., presents a clinical scenario and question based on the Cochrane Abstract, along with the evidence-based answer and a full critique of the abstract.
Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Jun 15, 2016
Access the latest issue of American Family Physician